Sagiv O, et al. - Researchers assessed the neoadjuvant use of vismodegib followed by surgery in patients with locally advanced periocular basal cell carcinoma (BCC) with primary goal being eye preservation. They treated patients for a median of 14 months (range: 4–36 months). Eye-sparing surgery after neoadjuvant vismodegib was conducted in all patients and all final surgical margins were negative for tumor. In all patients in this cohort, eye-sparing surgery was enabled by neoadjuvant vismodegib for locally advanced periocular BCC. Most patients tolerated the prolonged treatment well. A complete response was achieved by over half of patients with no residual microscopic disease.